Vaccine Company to be acquired by Lilly to advance best-in-class vaccine candidates for Epstein-Barr Virus and other infectious diseases
Vaccine Company (GLSI) has entered a definitive agreement to be acquired by Eli Lilly (LLY) for up to $1.55 billion in cash. The deal includes an upfront payment and subsequent milestone payments tied to clinical and commercial achievements for Vaccine Company's pipeline. The acquisition centers on Vaccine Company's proprietary In Vivo Nanoparticle (IVN) platform and its lead Phase 1-ready vaccine candidate for Epstein-Barr Virus (EBV).
Key figures
- Deal Value Usd
- 1550000000
- Upfront payment
- included in total
- Milestone payments
- included in total
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.